Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2020-A02325-34 | Other Identifier | ID RCB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The important evidence of coronary microcirculation for the management of patients with coronary artery disease is only increasing. Thus, in recent years, a number of studies have shown that the demonstration of coronary microvascular disease (CMVD) contributes to cardiovascular morbidity and mortality increases independently of epicardial damage. This has been shown in stable coronary artery disease with screening for CMVD when there is no significant epicardial involvement and allowing the implementation of an adapted treatment then reducing the symptoms and improving the quality of life of our patients. (1). The prognostic nature of CMVD has also been identified in stable disease after coronary angioplasty (2) but also in patients with infarcts reperfused by coronary angioplasty (3).
The complete exploration of the epicardial and microvascular coronary vascularization is grouped under the name of the subspecialty: coronary physiology. Thus, an internationally recognized algorithm for exploring coronary physiology has been published (4).
However, this algorithm is still little followed. The PRINCIPE registry aims to assess the prevalence of CMVD with the use of a standardized algorithm for exploring coronary physiology by coronary angiography in our center in current practice.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Rate of CMVD defined by microcirculatory resistance index (IMR) > 25 | At inclusion |
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence of macro and microvascular angina | Macro and microvascular angina rate according to international angiographic diagnostic criteria | At inclusion |
| Correlation between coronary physiology parameters and imaging data |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Any patient undergoing coronary artery assessment. Patients will be included in the study prospectively during the assessment with collection of the patient's non-objection during follow-ups.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Gilles Barone Rochette, MD PhD | Contact | +33476768888 | gbarone@chu-grenoble.fr | |
| Clemence Charlon, MSc | Contact | +33476766652 | ccharlon@chu-grenoble.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Grenoble University Hospital | Recruiting | La Tronche | 38700 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Coronary angiography and coronary physiology parameters:% of epicardial stenosis, FFR, CFR, IMR
| At inclusion |
| Correlation between coronary physiology parameters and imaging data | SPEC parameters | At inclusion |
| Correlation between coronary physiology parameters and imaging data | Cardiac echography parameters | At inclusion |
| Correlation between coronary physiology parameters and imaging data | Stress cardiac echography parameters | At inclusion |
| Correlation between coronary physiology parameters and imaging data | MRI parameters | At inclusion |
| Correlation between coronary physiology parameters and imaging data | Cardiac CT parameters | At inclusion |
| Assessment of the symptoms of angina pectoris | Brief angina questionnaire | 12 months |
| Compare the rate of peri-procedural myocardial distress | Post PCI troponin rate | At inclusion |
| Evaluate medical consumption | Number of medical consultation | 12 months |
| Evaluation of serious cardiovascular event rate | Cardiovascular event | 12 months |